<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04725500</url>
  </required_header>
  <id_info>
    <org_study_id>SRC-HRC-VectorENG -2018-10241</org_study_id>
    <nct_id>NCT04725500</nct_id>
  </id_info>
  <brief_title>Vector Engineering Clinical</brief_title>
  <official_title>Engineering Evaluation of the Vector NIV Device in Chronic Obstructive Pulmonary Disease (COPD) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philips Clinical &amp; Medical Affairs Global</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philips Clinical &amp; Medical Affairs Global</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to validate a novel automatic non-invasive ventilation (NIV) mode that&#xD;
      continuously adjusts expiratory positive airway pressure (EPAP) to the lowest value that&#xD;
      abolishes tidal expiratory flow limitation (EFL). The investigator conducted a prospective,&#xD;
      non-randomized, study on stable chronic obstructive pulmonary disease (COPD) patients that&#xD;
      may or may not be treated currently with NIV. Patients were studied in a sleep lab on a&#xD;
      single night with the auto - titrating EPAP that adjusts to abolish tidal EFL. The primary&#xD;
      endpoint was to evaluate the behavior of the EPAP during the night. Additionally, a sub-group&#xD;
      of patients used the device at home for a 2 week period. EPAP behavior was assessed during&#xD;
      this 2 week period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tidal Expiratory Flow Limitation (EFLT) is the inability to increase expiratory flow despite&#xD;
      increasing effort. Especially in patients with mild to severe COPD, EFL can present&#xD;
      challenges when receiving mechanical ventilation. To overcome EFLT expiratory positive airway&#xD;
      pressure (EPAP) is applied; however, a single level or fixed EPAP may not overcome the&#xD;
      airflow obstruction. The current study was undertaken to explore the variability of EFLT&#xD;
      determined using Forced Oscillation Technique (FOT) to dynamically measure lung reactance&#xD;
      (∆Xrs) and to evaluate the ability of automatically adjusted EPAP (PEEPopt) to over come EFLT&#xD;
      overnight and over a two week period.&#xD;
&#xD;
      In this prospective non-randomized trial, an unreleased noninvasive ventilator set in an S/T&#xD;
      mode applied continuous oscillations (5 Hz, 1 cmH2O amplitude, 2 cmH20 peak to peak).&#xD;
      Response to the oscillations was analyzed to calculate ∆Xrs and EPAP was adjusted&#xD;
      automatically between 4 and 20 cmH2O. A fixed pressure support of 6 cmH2O was delivered. ∆Xrs&#xD;
      was measured sitting and supine. Participants with evidence of EFLT (∆Xrs &gt; 2.8) were asked&#xD;
      to undergo overnight polysomnography (PSG) and then a sub-group of patients used the&#xD;
      ventilator at home for two weeks. EFLT within and between participants was analyzed. EFLT&#xD;
      behavior during PSG, the response of the device to dynamically abolish EFLT, as well as the&#xD;
      impact of this therapy on sleep quality was studied. Objective ventilator adherence data were&#xD;
      used to determine usage after the 2-week in-home use. Additionally, experienced NIV&#xD;
      participants qualitatively rated therapy comfort compared to their current treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 4, 2018</start_date>
  <completion_date type="Actual">March 3, 2020</completion_date>
  <primary_completion_date type="Actual">March 3, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average EPAP During Overnight PSG</measure>
    <time_frame>Approximately 8 hours</time_frame>
    <description>The expiratory positive airway pressure (EPAP) is the parameter that is automatically adjusted. The ventilator automatically titrates EPAP to the minimum value able to abolish expiratory flow limitation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference Between Mean Inspiratory and Expiratory Reactance During Overnight PSG</measure>
    <time_frame>Approximately 8 hours</time_frame>
    <description>The difference between mean inspiratory and expiratory reactance is measured using the forced oscillation technique. The difference between mean inspiratory and expiratory reactance is an index of tidal expiratory flow limitation. Values &gt; 2.8 cmH2O*s/L are indicative of tidal expiratory flow limitation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average EPAP for 2 Week Device Take Home Studies</measure>
    <time_frame>Approximately 8 hours nightly use over 14 days</time_frame>
    <description>The expiratory positive airway pressure (EPAP) is the parameter that is automatically adjusted. The ventilator automatically titrates EPAP to the minimum value able to abolish expiratory flow limitation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference Between Mean Inspiratory and Expiatory Reactance During 2 Week Device Take Home Studies</measure>
    <time_frame>2 weeks</time_frame>
    <description>The difference between mean inspiratory and expiatory reactance is measured using the forced oscillation technique. The difference between mean inspiratory and expiratory reactance is an index of tidal expiratory flow limitation. Values &gt; 2.8 cmH2O*s/L are indicative of tidal expiratory flow limitation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality</measure>
    <time_frame>Approximately 8 hours</time_frame>
    <description>Sleep quality is a key outcome during overnight studies. Nocturnal non-invasive ventilation may affect sleep quality in two ways: 1) it may improve it by reducing sleep-related respiratory problems; 2) it may worsen it if the ventilation mode causes discomfort to the patient. Sleep quality was evaluated by full laboratory polysomnography. Participants after there overnight answered a question of comfort and they answered as 1- being very uncomfortable 2- uncomfortable 3- neutral 4- comfortable 5- very comfortable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Week Home Use Device Compliance</measure>
    <time_frame>Nightly use for 14 days</time_frame>
    <description>Device usage every day, for 14 days based on data downloaded from the device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy Comfort Survey</measure>
    <time_frame>End of 2 weeks device take home study</time_frame>
    <description>Prior NIV users rated their comfort with the Forced Oscillation Technique (FOT) therapy over their prior non-invasive ventilation (NIV) therapy. Participants were asked the question &quot;how comfortable did the pressure therapy feel compared to your current device&quot; and they answered the questions on a scale of 0 to 5.&#xD;
5-Very Comfortable 4-Comfortable 3-Neutral 2-Uncomfortable&#xD;
1-Very Uncomfortable 0-Not applicable</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Auto-titrating EPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ExpiraFlowTM technology- Non-invasive ventilator that auto titrates EPAP to abolish Expiratory flow limitation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Auto-Titrating EPAP</intervention_name>
    <description>In the Auto-titrating EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.</description>
    <arm_group_label>Auto-titrating EPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 40 years of age; &lt; 80 years of age&#xD;
&#xD;
          2. Ability to provide consent&#xD;
&#xD;
          3. Diagnosis of COPD&#xD;
&#xD;
          4. Must present with EFL via screening of the vector device at 3 cmH2O&#xD;
&#xD;
          5. Have an EPAP to abolish EFL greater or equal to 6cmH2O&#xD;
&#xD;
          6. Must be able to maintain SpO2 greater than 88% at rest and during EPAP Titration&#xD;
&#xD;
          7. Participants who completed the initial study and who would be willing to use the&#xD;
             Vector NIV device at home during the night for a 2 week period OR&#xD;
&#xD;
          8. Participants prescribed and currently using a PAP or NIV device at home who meet study&#xD;
             inclusion/exclusion criteria of primary protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any major non COPD uncontrolled disease or condition, such as congestive heart&#xD;
             failure, malignancy, liver or renal insufficiency (that requires current evaluation&#xD;
             for liver or renal transplantation or dialysis), amyotrophic lateral sclerosis, or&#xD;
             severe stroke, or other condition as deemed appropriate by investigator as determined&#xD;
             by review of medical history and / or participant reported medical history&#xD;
&#xD;
          2. Suffering from a COPD exacerbation at the time of data collection or in the 30 days&#xD;
             prior to data collection&#xD;
&#xD;
          3. Self-reported Pregnancy&#xD;
&#xD;
          4. Employee or family member that is affiliated with Philips Respironics&#xD;
&#xD;
          5. Currently employed by a manufacturer of respiratory products or family member employed&#xD;
             by a manufacturer of respiratory products&#xD;
&#xD;
          6. History of bullous emphysema&#xD;
&#xD;
          7. History of pneumothorax&#xD;
&#xD;
          8. Evidence of acute sinusitis or otitis media&#xD;
&#xD;
          9. Hypotension&#xD;
&#xD;
         10. Participants at risk for aspiration of gastric contents&#xD;
&#xD;
         11. Epistaxis&#xD;
&#xD;
         12. Participants in respiratory failure&#xD;
&#xD;
         13. Inability to maintain a patent airway or adequately clear secretions&#xD;
&#xD;
         14. Participants currently using a PAP or NIV device at home with a documented EPAP&#xD;
             setting on their current device that is greater than then the mean or final EPAP&#xD;
             determined during the therapy session of the screening visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pulmonary Rehabilitation Associates</name>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <zip>44512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jefferson Associates and Internal Medicine</name>
      <address>
        <city>Clairton</city>
        <state>Pennsylvania</state>
        <zip>15025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <results_first_submitted>March 10, 2021</results_first_submitted>
  <results_first_submitted_qc>March 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 6, 2021</results_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non Invasive Ventilation</keyword>
  <keyword>Expiratory Flow Limitation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT04725500/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Auto-titrating EPAP</title>
          <description>ExpiraFlowTM technology- Non-invasive ventilator that auto titrates EPAP to abolish Expiratory flow limitation.&#xD;
Auto-Titrating EPAP: In the Auto-titrating EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Screening</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Overnight Polysomnography (PSG)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>2 Week Take Home</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen Fail</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants that signed a consent form.</population>
      <group_list>
        <group group_id="B1">
          <title>Auto-titrating EPAP</title>
          <description>ExpiraFlowTM technology- Non-invasive ventilator that auto titrates EPAP to abolish Expiratory flow limitation.&#xD;
Auto-Titrating EPAP: In the Auto-titrating EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.4" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced Expiratory Volume in one second / Forced Vital Capacity</title>
          <population>Historical Spirometry data was collected not all participants had the FEV1/FVC values available.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average EPAP During Overnight PSG</title>
        <description>The expiratory positive airway pressure (EPAP) is the parameter that is automatically adjusted. The ventilator automatically titrates EPAP to the minimum value able to abolish expiratory flow limitation.</description>
        <time_frame>Approximately 8 hours</time_frame>
        <population>PSG data was not available for one participant.</population>
        <group_list>
          <group group_id="O1">
            <title>Auto-titrating EPAP</title>
            <description>ExpiraFlowTM technology- Non-invasive ventilator that auto titrates EPAP to abolish Expiratory flow limitation.&#xD;
Auto-Titrating EPAP: In the Auto-titrating EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.</description>
          </group>
        </group_list>
        <measure>
          <title>Average EPAP During Overnight PSG</title>
          <description>The expiratory positive airway pressure (EPAP) is the parameter that is automatically adjusted. The ventilator automatically titrates EPAP to the minimum value able to abolish expiratory flow limitation.</description>
          <population>PSG data was not available for one participant.</population>
          <units>cmH2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Difference Between Mean Inspiratory and Expiratory Reactance During Overnight PSG</title>
        <description>The difference between mean inspiratory and expiratory reactance is measured using the forced oscillation technique. The difference between mean inspiratory and expiratory reactance is an index of tidal expiratory flow limitation. Values &gt; 2.8 cmH2O*s/L are indicative of tidal expiratory flow limitation.</description>
        <time_frame>Approximately 8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Auto-titrating EPAP</title>
            <description>ExpiraFlowTM technology- Non-invasive ventilator that auto titrates EPAP to abolish Expiratory flow limitation.&#xD;
Auto-Titrating EPAP: In the Auto-titrating EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between Mean Inspiratory and Expiratory Reactance During Overnight PSG</title>
          <description>The difference between mean inspiratory and expiratory reactance is measured using the forced oscillation technique. The difference between mean inspiratory and expiratory reactance is an index of tidal expiratory flow limitation. Values &gt; 2.8 cmH2O*s/L are indicative of tidal expiratory flow limitation.</description>
          <units>cmH20/L/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average EPAP for 2 Week Device Take Home Studies</title>
        <description>The expiratory positive airway pressure (EPAP) is the parameter that is automatically adjusted. The ventilator automatically titrates EPAP to the minimum value able to abolish expiratory flow limitation.</description>
        <time_frame>Approximately 8 hours nightly use over 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Auto-titrating EPAP</title>
            <description>ExpiraFlowTM technology- Non-invasive ventilator that auto titrates EPAP to abolish Expiratory flow limitation.&#xD;
Auto-Titrating EPAP: In the Auto-titrating EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.</description>
          </group>
        </group_list>
        <measure>
          <title>Average EPAP for 2 Week Device Take Home Studies</title>
          <description>The expiratory positive airway pressure (EPAP) is the parameter that is automatically adjusted. The ventilator automatically titrates EPAP to the minimum value able to abolish expiratory flow limitation.</description>
          <units>cm H2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Difference Between Mean Inspiratory and Expiatory Reactance During 2 Week Device Take Home Studies</title>
        <description>The difference between mean inspiratory and expiatory reactance is measured using the forced oscillation technique. The difference between mean inspiratory and expiratory reactance is an index of tidal expiratory flow limitation. Values &gt; 2.8 cmH2O*s/L are indicative of tidal expiratory flow limitation.</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Auto-titrating EPAP</title>
            <description>ExpiraFlowTM technology- Non-invasive ventilator that auto titrates EPAP to abolish Expiratory flow limitation.&#xD;
Auto-Titrating EPAP: In the Auto-titrating EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between Mean Inspiratory and Expiatory Reactance During 2 Week Device Take Home Studies</title>
          <description>The difference between mean inspiratory and expiatory reactance is measured using the forced oscillation technique. The difference between mean inspiratory and expiratory reactance is an index of tidal expiratory flow limitation. Values &gt; 2.8 cmH2O*s/L are indicative of tidal expiratory flow limitation.</description>
          <units>cmH20/L/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality</title>
        <description>Sleep quality is a key outcome during overnight studies. Nocturnal non-invasive ventilation may affect sleep quality in two ways: 1) it may improve it by reducing sleep-related respiratory problems; 2) it may worsen it if the ventilation mode causes discomfort to the patient. Sleep quality was evaluated by full laboratory polysomnography. Participants after there overnight answered a question of comfort and they answered as 1- being very uncomfortable 2- uncomfortable 3- neutral 4- comfortable 5- very comfortable.</description>
        <time_frame>Approximately 8 hours</time_frame>
        <population>2 participants completed a different version of the questionnaire. 1 participant did not morning assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Auto-titrating EPAP</title>
            <description>ExpiraFlowTM technology- Non-invasive ventilator that auto titrates EPAP to abolish Expiratory flow limitation.&#xD;
Auto-Titrating EPAP: In the Auto-titrating EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality</title>
          <description>Sleep quality is a key outcome during overnight studies. Nocturnal non-invasive ventilation may affect sleep quality in two ways: 1) it may improve it by reducing sleep-related respiratory problems; 2) it may worsen it if the ventilation mode causes discomfort to the patient. Sleep quality was evaluated by full laboratory polysomnography. Participants after there overnight answered a question of comfort and they answered as 1- being very uncomfortable 2- uncomfortable 3- neutral 4- comfortable 5- very comfortable.</description>
          <population>2 participants completed a different version of the questionnaire. 1 participant did not morning assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Comfortable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very Comfortable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2 Week Home Use Device Compliance</title>
        <description>Device usage every day, for 14 days based on data downloaded from the device.</description>
        <time_frame>Nightly use for 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Auto-titrating EPAP</title>
            <description>ExpiraFlowTM technology- Non-invasive ventilator that auto titrates EPAP to abolish Expiratory flow limitation.&#xD;
Auto-Titrating EPAP: In the Auto-titrating EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.</description>
          </group>
        </group_list>
        <measure>
          <title>2 Week Home Use Device Compliance</title>
          <description>Device usage every day, for 14 days based on data downloaded from the device.</description>
          <units>hours of therapy per night</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Therapy Comfort Survey</title>
        <description>Prior NIV users rated their comfort with the Forced Oscillation Technique (FOT) therapy over their prior non-invasive ventilation (NIV) therapy. Participants were asked the question &quot;how comfortable did the pressure therapy feel compared to your current device&quot; and they answered the questions on a scale of 0 to 5.&#xD;
5-Very Comfortable 4-Comfortable 3-Neutral 2-Uncomfortable&#xD;
1-Very Uncomfortable 0-Not applicable</description>
        <time_frame>End of 2 weeks device take home study</time_frame>
        <population>2 participants did not complete final assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Auto-titrating EPAP</title>
            <description>ExpiraFlowTM technology- Non-invasive ventilator that auto titrates EPAP to abolish Expiratory flow limitation.&#xD;
Auto-Titrating EPAP: In the Auto-titrating EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.</description>
          </group>
        </group_list>
        <measure>
          <title>Therapy Comfort Survey</title>
          <description>Prior NIV users rated their comfort with the Forced Oscillation Technique (FOT) therapy over their prior non-invasive ventilation (NIV) therapy. Participants were asked the question &quot;how comfortable did the pressure therapy feel compared to your current device&quot; and they answered the questions on a scale of 0 to 5.&#xD;
5-Very Comfortable 4-Comfortable 3-Neutral 2-Uncomfortable&#xD;
1-Very Uncomfortable 0-Not applicable</description>
          <population>2 participants did not complete final assessment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Not Applicable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Uncomfortable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very Comfortable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through 2 week take home</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Auto-titrating EPAP</title>
          <description>ExpiraFlowTM technology- Non-invasive ventilator that auto titrates EPAP to abolish Expiratory flow limitation.&#xD;
Auto-Titrating EPAP: In the Auto-titrating EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol detox</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute COPD Exacerbation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chuck Cain</name_or_title>
      <organization>Philips</organization>
      <phone>412-657-1814</phone>
      <email>chuck.cain@philips.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

